| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
3,343,000 |
| Market
Cap: |
1.68(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.431 - $1.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evoke Pharma is a pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Co. is developing its primary product, Gimoti™ (metoclopramide) nasal spray, a nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Diabetic gastroparesis is a GI disorder, in which food in an individual's stomach takes too long to empty resulting in a variety of GI symptoms and systemic metabolic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Halak Brian K |
10% Owner |
– – • |
2015-04-15 |
4 |
S |
$7.58 |
$1,023 |
D/D |
(135) |
18,703 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2015-04-14 |
4 |
S |
$7.78 |
$76,493 |
D/D |
(9,832) |
1,104,495 |
|
- |
|
| Halak Brian K |
10% Owner |
– – • |
2015-04-14 |
4 |
S |
$7.78 |
$1,307 |
D/D |
(168) |
18,838 |
|
- |
|
| Carlson Marilyn R. |
Chief Medical Officer |
• – – |
2015-02-27 |
4 |
A |
$4.75 |
$28,776 |
D/D |
6,058 |
7,314 |
|
- |
|
| Gonyer David A |
President and CEO |
• • – |
2015-02-27 |
4 |
A |
$4.75 |
$12,877 |
D/D |
2,711 |
283,711 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2015-02-27 |
4 |
A |
$4.75 |
$31,687 |
D/D |
6,671 |
201,671 |
|
- |
|
| Shah Nimesh |
10% Owner |
– – • |
2015-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,250 |
|
- |
|
| Brady Todd C |
Director |
– • – |
2014-09-23 |
4 |
B |
$5.70 |
$22,802 |
D/D |
4,000 |
4,000 |
2.39 |
- |
|
| Hill Malcolm R |
Director |
– • – |
2014-09-03 |
4 |
OE |
$0.29 |
$1,523 |
D/D |
5,250 |
19,250 |
|
- |
|
| Carlson Marilyn R. |
Chief Medical Officer |
• – – |
2014-08-29 |
4 |
A |
$5.67 |
$7,122 |
D/D |
1,256 |
1,256 |
|
- |
|
60 Records found
|
|
Page 3 of 3 |
|
|
0.02 (4.62%) 
